Company / SG&A per Share
Matinas BioPharma Holdings, Inc. SG&A per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$2.01
FY2024
5-year range
$0.05 / $2.01
FY2020-FY2024
Trend
+3832.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A per Share changed +3832% YoY in FY2024, a notable deviation from the 9-year average annual change of +416%.
Based on SEC 10-K filings.
2.01 in FY2024 with a 5-year CAGR of +95.5%.
Increased from $0.05 to $2.01 over the past 2 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +240.5%
- 5-Year CAGR
- +95.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, sg&a per share increased 3832.0% year-over-year.
- Lowest sg&a per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.01 | +3832.0% |
| FY2023 | $0.05 | +8.5% |
| FY2022 | $0.05 | -7.5% |
| FY2021 | $0.05 | -17.0% |
| FY2020 | $0.06 | -12.9% |
| FY2019 | $0.07 | -13.9% |
| FY2018 | $0.08 | -1.1% |
| FY2017 | $0.08 | +9.8% |
| FY2016 | $0.08 | -49.4% |
| FY2015 | $0.15 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026